STAT
OCTOBER 8, 2024
A trade group representing large compounding pharmacies has sued the U.S. Food and Drug Administration for a “reckless and arbitrary” decision to remove a widely prescribed Eli Lilly drug for combating diabetes and obesity from an official shortages list.
STAT
MAY 22, 2024
Data presented this week at the Digestive Disease Week meeting in D.C. Australia to ban compounded versions of blockbuster drugs Ozempic and Mounjaro, Reuters reports. A drug often used off-label to treat alcohol use disorder might provide better benefits than therapies approved for this indication, STAT tells us.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
OCTOBER 8, 2024
So join us as we hoist the ever-present cup of stimulation — our choice today is coconut rum — and attack the fast-growing to-do list. … A trade group representing large compounding pharmacies has sued the U.S. We trust you have your own hectic agendas. Have a grand day, everyone, and do stay in touch.
Omnicell
SEPTEMBER 5, 2022
Terri Albarano, PharmD Director, Autonomous Pharmacy, Omnicell Sterile compounding safety is one of the biggest challenges for the pharmacy supply chain. Health systems are expected to compound IV preparations with increasingly complex regulations, rising drug costs, and supply disruptions. Injectable medications cause 1.2
Omnicell
JANUARY 10, 2023
Many often rely on 503B outsourcing pharmacies for their pre-mixed compounded sterile products. At the University of Maryland Medical Center, we reduced our need for 503B vendors by implementing an IV robotics insourcing program for compounded sterile products (CSPs).
STAT
OCTOBER 24, 2023
MADRID — If you had to pinpoint one subject that stood out at this year’s European Society for Medical Oncology meeting , a massive conference with thousands of people from 140-some countries and 2,500 studies presented, it would be a burgeoning type of cancer treatment called antibody-drug conjugates.
The FDA Law Blog
AUGUST 14, 2023
Farquhar — At the GMP by the Sea Conference ongoing in Cambridge, Maryland, a presentation was made by a representative of FDA’s Center for Drug Evaluation and Research that shows some interesting trends in enforcement. By Douglas B. OAI is FDA’s classification for facilities it deems to be in an unacceptable state of compliance.
Expert insights. Personalized for you.
138 
Let's personalize your content